Healthcare Industry News:  Pharmos 

Biopharmaceuticals Personnel

 News Release - February 25, 2008

Akrimax Pharmaceuticals Announces New President

Industry Leader Alan L. Rubino Joins New Company

CRANFORD, N.J.--(HSMN NewsFeed)--Akrimax Pharmaceuticals, LLC announced today the appointment of experienced pharmaceutical industry executive Alan L. Rubino as its new President.

Rubino has spent 30 years at every level of the pharmaceutical industry, and most recently was the President and Chief Operating Officer of Pharmos Corporation where he led the transformation of the company through the acquisition of Vela Pharmaceuticals and subsequent restructuring of Pharmos to focus on its leading development compound currently in Phase 2b clinical trials for the treatment of irritable bowel syndrome.

“We are thrilled that Alan has agreed to join Akrimax,” said Joseph Krivulka, Chairman of Akrimax. “His experience in building long-term value and strategic alliances with industry partners is exactly what we want. And his extensive industry knowledge will bring new opportunities for Akrimax and our customers.”

Rubino’s appointment adds to a deep and successful senior management team that formed Akrimax late last year, and purchased the 950,000-sq.-foot manufacturing facility in Rouses Point, New York and select pharmaceutical products from Wyeth. Krivulka founded the company with co-chairman Leonard Mazur.

Rubino is accomplished in a multitude of therapeutic areas with comprehensive knowledge and product marketing experience in cardiovascular, CNS, oncology, gastroenterology, infectious diseases, dermatology and biotechnology.

Prior to joining Pharmos, Rubino spent 24 years at Hoffmann-La Roche, one of the world’s top ten pharmaceutical companies and a global leader in the diagnostics sector. At Roche, he was a corporate officer and member of the U.S. executive committee, holding a variety of key positions with broad management responsibilities in operations, marketing, business development, human resources and corporate strategy.

“Joining the Akrimax team is a great opportunity as they have a proven track record of building highly successful companies,” Rubino said. “Akrimax is a fast-growing and ambitious new company and I look forward to being part of its development and growth as we become a major specialty pharma player that also possesses significant capabilities to be among the best strategic manufacturing partners in the industry.”


Akrimax Pharmaceuticals, LLC is a privately-held, fully-integrated emerging specialty pharmaceutical company that will concentrate its branded focus on products for the treatment of metabolic syndrome and other diseases with unsurpassed quality in the development, production, manufacturing, distribution, and commercialization of a full range of top-quality pharmaceutical products. Akrimax currently markets Inderal LA and LoOvral branded products and operates the Rouses Point manufacturing facility in conjunction with Wyeth during a transition period that runs through 2009. The facility will continue manufacturing Wyeth products, while Akrimax begins integrating its own products and those of its third-party customers.

Source: Akrimax Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.